# 1 **Improved NAAT assay for the diagnosis of onchocerciasis and its use for**

2 **detection of circulating cell free DNA**<br>3 Sasisekhar Bennuru<sup>1</sup>, Frimpong Kodua<sup>1\*\*</sup>, Eric Dahlstrom<sup>2</sup>, Thomas B Nutman<sup>1</sup>

4

### 4

5 **Affiliations:**  1

<sup>1</sup>Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, MD USA<br>7 <sup>2</sup>Genomics Unit, Research Technologies Branch, NIAID, NIH, Hami 2

<sup>2</sup>Genomics Unit, Research Technologies Branch, NIAID, NIH, Hamilton, USA.<br>8 <sup>\*\*</sup>Howard University Hospital, Department of Internal Medicine, Washington D 8 \*\*Howard University Hospital, Department of Internal Medicine, Washington DC, USA<br>9

### 10

- 10 **Abstract**<br>11 Mass drug administration (MDA) programs aimed at control and elimination of
- 12 onchocerciasis relies on annual or semi-annual distribution of Ivermectin (IVM) that
- 12 onchocerciasis relies on annual or semi-annual distribution of Ivermectin (IVM) that<br>13 target the microfialarial (mf) stage of the parasite *Onchocerca volvulus*. The co-
- 13 target the microfialarial (mf) stage of the parasite *Onchocerca volvulus*. The co-

14 endemicity of onchocerciasis with other filarial species often leads to interruptions in the<br>15 control programs. A much-needed tool for the elimination efforts are sensitive diagnostic 15 control programs. A much-needed tool for the elimination efforts are sensitive diagnostic<br>16 assays that can help differentiate from other co-endemic filarial infections or

- 
- 16 assays that can help differentiate from other co-endemic filarial infections or<br>17 xenomonitoring approaches. qPCR assays targeting highly repeated elements in the
- 18 qenomes have allowed for increased sensitivity of detection that are pathogen-specific.
- 19 Utilizing NGS data, gPCR assays were designed to target 15 highly repeated targets
- 19 Utilizing NGS data, qPCR assays were designed to target 15 highly repeated targets<br>20 from *O. volvulus* and 11 from *O. ochengi.* The two most sensitive and specific repeats
- 20 from *O. volvulus* and 11 from *O. ochengi*. The two most sensitive and specific repeats 21 Ov15R and Ov16R from *O. volvulus* and OoR1 and OoR5 from *O. ochengi*, were
- selected for further testing.



41<br>42

**Introduction**<br>43 *Onchocerca volvulus* is a filarial parasite that causes onchocerciasis or more often *Ioncerca volvers viver blindness'* and is transmitted by the bites of Simulium blackfly species known as 'river blindness' and is transmitted by the bites of *Simulium* blackfly species 45 primarily endemic to sub-Saharan Africa. Control efforts for elimination of the disease as<br> 46 a major public health concern relies on the mass drug administration (MDA) programs<br>47 with annual or semi-annual distribution of Ivermectin (IVM). Only the microfilarial (mf) 48 stages of the parasite are effectively targeted using IVM that help to reduce disease 49 burden and block transmission to the blackfly vectors (Simulium sp). Based on the 49 burden and block transmission to the blackfly vectors (*Simulium* sp). Based on the 50 microfilarial prevalence, endemic regions can be broadly categorized into hypoendemic<br>51 (<30-35%), mesoendemic (30-35% to 60%) and hyperendemic (<u>></u> 60%). 51 (<30-35%), mesoendemic (30-35% to 60%) and hyperendemic ( $\geq 60$ %).<br>52 A much-needed tool for the elimination efforts is a specific and sensitive

53 diagnostic assay that can verify if the levels of transmission of the disease are low 54 enough to warrant the cessation of MDA or in regions of post-MDA surveillance for 55 monitoring resurgence of infection. The use-case scenario for the assay relies on the 56 assay(s) to have high sensitivity and specificity, to detect very low-levels of mf densities 56 assay(s) to have high sensitivity and specificity, to detect very low-levels of mf densities<br>57 while being able to discriminate between closely related co-endemic major filarial 57 while being able to discriminate between closely related co-endemic major filarial<br>58 parasites that infect humans such as *Loa loa, Wuchereria bancrofti, Mansonella* 58 parasites that infect humans such as *Loa loa*, *Wuchereria bancrofti, Mansonella*  59 *perstans* and the bovine filarial parasite *Onchocerca ochengi* that is also transmitted by 60 the same vector species. Another major concern is the presence of *Loa loa* microfilariae 61 in the skin-snips of infected individuals in co-endemic areas [1] that often lead to false<br>62 interpretations. 62 interpretations.<br>63 Historically, the identification of microfilariae in the skin snips by microscopy was

64 the 'gold standard' for diagnosis of infection. Though skin snip microscopy is 100% 64 the 'gold standard' for diagnosis of infection. Though skin snip microscopy is 100% 65 specificity it is plagued with low sensitivity (estimated at 20%) esp. in areas with low mf<br>66 densities[2]. 66 densities[2].<br>67 The quidelines from World Health organization (WHO) for stopping MDA and verifying

67 The guidelines from World Health organization (WHO) for stopping MDA and verifying<br>68 elimination of onchocerciasis as a major public health concern recommends serologica 68 elimination of onchocerciasis as a major public health concern recommends serological

69 evaluation for Ov16 by ELISA or rapid diagnostic test (RDT) [3], where the seropositivity<br>60 to Ov16 in children younger than 10 years should be <0.1% and positivity of pool screen 71 PCR of at least 6000 black fly heads to be <0.05%, the diagnostic performance 72 thresholds of which depend on multiple factors [3, 4]. The Ov-16 antibody test 73 determines the presence of IgG4 antibodies to Ov-16 as a marker of exposure to the 74 parasite [5-8]. Entomological screening for the presence of infective L3 larvae in the 75 vector population relies on the PCR based amplification of O-150 repeat family region of 76 parasite DNA [9-11]. Though there is some conservation of the O-150 tandem repeats 77 sequences across the Onchocerca spp., the tandem repeats not only vary in the 78 number but also not always identical repeats. In addition to the detection of O-150, 79 assays based on real-time qPCR and loop mediated isothermal amplification (LAMP) 80 have been developed to detect O. volvulus DNA in the skin [12]. Skin snip evaluation 80 have been developed to detect *O. volvulus* DNA in the skin [12]. Skin snip evaluation 81 by PCR could be used to also differentiate active infection from exposure to the parasite<br>82 where the prevalence of Ov-16 seropositivity is > 0.1% [3]. However, skin snips being 82 where the prevalence of Ov-16 seropositivity is > 0.1% [3]. However, skin snips being<br>83 more invasive in nature are becoming increasingly unpopular and often refused by 84 endemic communities [13]. Recent studies explored the detectability of circulating filarial 84 endemic communities [13]. Recent studies explored the detectability of circulating filarial<br>85 DNA for *B. malayi* [14], *L. loa* [15] or *Onchocerca* spp [16]. Though parasite-derived 85 DNA for *B. malayi* [14], *L. loa* [15] or *Onchocerca* spp [16]. Though parasite-derived 86 miRNAs were detected in the plasma of *O. volvulus* infected individuals, their detection 87 as a biomarker has been challenging and were determined to be insufficient tools or as<br>88 biomarkers of treatment efficacy for *O. volvulus* [16, 17]. Detecting circulating cell-free 88 biomarkers of treatment efficacy for *O. volvulus* [16, 17]. Detecting circulating cell-free 89 DNA in body fluids (serum/plasma or urine) provides a promising alternative where<br>90 Sample collection is more convenient or less invasive. sample collection is more convenient or less invasive.



113 processed to trim, clean and obtain paired reads. The RepeatExplorer [24, 25] pipeline



137 disc (as backing support membrane) followed by the chitosan-functionalized disc were<br>138 positioned in the luer cap. Urine samples mixed 1:1 with 50 mM MES (pH 5.0) were 138 positioned in the luer cap. Urine samples mixed 1:1 with 50 mM MES (pH 5.0) were<br>139 passed through the luer caps using 20 ml syringes at a flow rate of 0.5 ml per minute 139 passed through the luer caps using 20 ml syringes at a flow rate of 0.5 ml per minute<br>140 using the PHD ULTRA (Harvard Apparatus). The DNA trapped on the chitosan-140 using the PHD ULTRA (Harvard Apparatus). The DNA trapped on the chitosan-<br>141 functionalized membrane was retrieved by boiling the disc in 50  $\mu$ l of deionized 141 functionalized membrane was retrieved by boiling the disc in 50 μl of deionized water.<br>142 **gPCR** was performed in quadruplicates using an ABI 7900 sequence detection 143 system using Tagman fast chemistry reagents (Applied Biosystems, Carlsbad, CA, USA) 143 system using Taqman fast chemistry reagents (Applied Biosystems,Carlsbad, CA, USA)<br>144 and primer/probe sets described in Table 1. Amplification conditions were 20 seconds 144 and primer/probe sets described in **Table 1**. Amplification conditions were 20 seconds 145 at 95°C followed by 40 cycles of 1 second at 95°C and 20 seconds at 60°C. An internal<br>146 plasmid control [28] was spiked into all samples prior to ccfDNA extraction to exclude 146 plasmid control [28] was spiked into all samples prior to ccfDNA extraction to exclude<br>147 false negatives due to qPCR inhibition. For a sample to be considered as positive at 147 false negatives due to qPCR inhibition. For a sample to be considered as positive at 148 least three of the 4 replicates needed to positive. An internal plasmid control [28] was<br>149 spiked into all samples prior to ccfDNA extraction to exclude false negatives due to 149 spiked into all samples prior to ccfDNA extraction to exclude false negatives due to<br>150 qPCR inhibition. 150 qPCR inhibition.<br>151 152 152 *Statistical analyses* 

153 All statistical analyses were performed using GraphPad Prism v8. Unpaired samples<br>154 were compared using Mann-Whitney test and paired analyses were performed with 154 were compared using Mann-Whitney test and paired analyses were performed with<br>155 Wilcoxon matched-pairs signed rank test. 155 Wilcoxon matched-pairs signed rank test.<br>156

157

157 **Results**  158 *O. volvulus and O. ochengi target identification*  159 The repeatexplorer pipeline [24, 25] resulted in the identification of several highly<br>160 repetitive contigs in the genomes of *O. volvulus* and *O. ochengi* of which, thirteen of the 161 most highly represented ones for *O. volvulus* and eleven of the *O. ochengi* contigs were 162 selected to be screened by qPCR (Figure 1). Preliminary screening with 10-fold 163 dilutions of 1ng/ul of *O. volvulus* genomic DNA (Ov gDNA) indicated that Ov15R, 164 Ov16R, Ov21R, Ov31R, Ov36R and Ov54R had better sensitivity than the other repeat 165 contigs (Figure 1A). Moreover, these six assays had better sensitivity (lower Ct values) 166 compared to the current gold standard O-150 qPCR (Figure 1B), of which Ov15R and 167 Cv16R were chosen for being the most sensitive assays. Ov15R and Ov16R assays 168 were similar in their limits of detection (1fg of gDNA) while maintaining specificity with 168 were similar in their limits of detection (1fg of gDNA) while maintaining specificity with<br>169 gDNA of *B. malayi, L. loa, W. bancrofti, M. perstans* and *O. ochengi* (Figure 1C). 169 gDNA of *B. malayi, L. loa, W. bancrofti, M. perstans* and *O. ochengi* (**Figure 1C**). 170 The eleven *O. ochengi* repeat contigs were screened with 2 assays designed for<br>171 each contig (R1-R22), of which R1 and R5 (henceforth referred to as OoR1 and OoR5) 172 were the most sensitive (lowest Ct value) when screened with 10 pg of O. ochengi 173 gDNA (Figure 1D). Screening of OoR1 and OoR5 with gDNA standards indicated the 173 gDNA (**Figure 1D**). Screening of OoR1 and OoR5 with gDNA standards indicated the<br>174 LOD of 100 fg with *O. ochengi* gDNA while maintaining specificity with *O. volvulus* 174 LOD of 100 fg with *O. ochengi* gDNA while maintaining specificity with *O. volvulus* 175 gDNA (**Figure 1E**).

### 177

177 *Relationship between O-150 and Ov15R/Ov16R*  178 Because Ov15R and Ov16R had better sensitivity (lower Ct values) compared to O-150<br>179 qPCR assay (<mark>Figure 2A</mark>), combinations of Ov15R and/or Ov16R were tested with O-179 qPCR assay (**Figure 2A**), combinations of Ov15R and/or Ov16R were tested with O-180 150 but did not yield any enhancements in the limits of detection. Sequence analyses<br>181 suggested that the selected *O. volvulus* contigs might be related somehow to O-150 ir 181 suggested that the selected *O. volvulus* contigs might be related somehow to O-150 in



205 Ov16R. As expected, the O150 results correlated similarly with O-150-New and Ov16R<br>206 Ct values, with O-150-New performing similarly to Ov16R in comparison to the O-150 206 Ct values, with O-150-New performing similarly to Ov16R in comparison to the O-150<br>207 (F<mark>igure 3E-G</mark>). 207 (**Figure 3E-G**).

208

209 *Plasma circulating cell-free DNA (ccfDNA)* 

210 To evaluate the efficacy of detecting Ov16R or O-150-New in ccfDNA derived from 211 plasma of infected individuals, pooled plasma of infected individuals or pooled plasma<br>212 of health blood bank individuals spiked with 100 pg of gDNA were used to extract

212 of health blood bank individuals spiked with 100 pg of gDNA were used to extract<br>213 ccfDNA. The ccfDNA extraction was carried out using plasma volumes of 100 μl, 250 μl,

214 500 µ and 1000 µl, using the MinElute ccfDNA kit (Qiagen) with elution volumes of 20

214 500 µl and 1000 µl, using the MinElute ccfDNA kit (Qiagen) with elution volumes of 20<br>215 µl for all samples. As shown in <mark>Figure 4A</mark>, ccfDNA derived from any of the pooled

215 µl for all samples. As shown in **Figure 4A**, ccfDNA derived from any of the pooled 216 samples (and volumes) from Ecuador or Guatemala failed to amplify Ov16R. As<br>217 expected, the ccfDNA from pooled blood bank individuals were negative but the spiked

217 expected, the ccfDNA from pooled blood bank individuals were negative but the spiked<br>218 samples were highly positive for Ov16R, suggesting that the lack of detectability is likely 218 samples were highly positive for Ov16R, suggesting that the lack of detectability is likely<br>219 due to the absence of detectable levels of parasite-derived DNA in circulation.

219 due to the absence of detectable levels of parasite-derived DNA in circulation.<br>220

221

221 *Urine circulating cell-free DNA (ccfDNA)*  222 Urine as a source of detecting the presence of ccfDNA was tested using archived<br>223 samples from previous studies (ref), that was aimed at understanding the immuno 223 samples from previous studies (ref), that was aimed at understanding the immunological<br>224 sequelae during Mazzotti reactions post treatment with ivermectin and followed up 224 sequelae during Mazzotti reactions post treatment with ivermectin and followed up<br>225 every 3-12 hours. ccfDNA was extracted from 1 ml of urine from 22 samples pre-225 every 3-12 hours. ccfDNA was extracted from 1 ml of urine from 22 samples pre-<br>226 treatment (18-infected and 4-controls). As shown in <mark>Figure 4B</mark>, 8/18 (44%) samp 226 treatment (18-infected and 4-controls). As shown in **Figure 4B**, 8/18 (44%) samples 227 were positive for Ov16R at time 0. Since ivermectin targets only the microfilarial stages,

228 and the death of microfilariae would result in parasite-derived DNA in circulation, we<br>229 screened the time-course samples for 4 individuals that were still available (2 each fo 229 screened the time-course samples for 4 individuals that were still available (2 each for<br>230 samples that were negative or positive at time 0). As expected, in the two samples that 230 samples that were negative or positive at time 0). As expected, in the two samples that<br>231 vere negative pre-treatment, Ov16R could be detected as early as 12-24 hours post-232 treatment (Figure 4C), that eventually clears away around 3-4 days post-treatment. In 232 treatment (**Figure 4C**), that eventually clears away around 3-4 days post-treatment. In 233 contrast, the two samples that were positive for Ov16R pre-treatment had varying levels<br>234 of detectability all through the time-course (<mark>Figure 4D</mark>).

234 of detectability all through the time-course (**Figure 4D**). 236 that has been frozen away for two decades compared to fresh urine, we obtained more 237 recent/fresh urine samples from 5 individuals from Cameroon, Surprisingly, ccfDNA 237 recent/fresh urine samples from 5 individuals from Cameroon. Surprisingly, ccfDNA<br>238 extracted from 1 ml of all five urine samples were positive for Ov16R (<mark>Figure 4E</mark>). 238 extracted from 1 ml of all five urine samples were positive for Ov16R (**Figure 4E**).

# 239<br>240

240 *Chitosan filter-based capture of ccfDNA*  242 processing of larger volumes with existing kits/reagents render it highly unusable. 243 Hence to evaluate the feasibility of capturing/trapping the ccfDNA, we adapted the 244 chitosan-modified filter paper technique (ref). Because of the non-availability of patient 244 chitosan-modified filter paper technique (ref). Because of the non-availability of patient<br>245 derived urine samples in higher volumes, pooled normal urine (1 or 15 ml) was spiked 245 derived urine samples in higher volumes, pooled normal urine (1 or 15 ml) was spiked<br>246 with various concentrations of *O. volvulus* gDNA and an internal control (IAC) and 246 with various concentrations of *O. volvulus* gDNA and an internal control (IAC) and 248 vith the spiked gDNA was also extracted on QiaSymphony. The filters were boiled in 30 248 with the spiked gDNA was also extracted on QiaSymphony. The filters were boiled in 30<br>249 ul of TE buffer (pH 8.0) to elute the DNA for qPCR detection. As shown in <mark>Figure 5</mark>, the 249 ul of TE buffer (pH 8.0) to elute the DNA for qPCR detection. As shown in **Figure 5**, the 250 efficiency of gDNA captured from 1 ml or 15 ml of urine and subsequent detectability of

251 Ov16R were identical, indicating that it is possible to filter out larger volumes of urine,<br>252 while capturing DNA.

- 252 while capturing DNA.<br>253
- 
- 253 254 *Discussion*
- 

255 256 This study reports the identification of genomic repeats enriched in the genomes of *O.*  257 *volvulus and O. ochengi.* Among those identified for *O. volvulus*, Ov16R was more 258 sensitive than O-150 by qPCR. Based on informatic analyses, O-150 and Ov16R are<br>259 related by way of their genomic location as they both map to one end of related by way of their genomic location as they both map to one end of<br>260 OVOC OO 000013, OVOC OO 00548 or OVOC OM1b of the O. volvulus genome. 261 The superiority of Ov16R to O-150 qPCR in terms of sensitivity was probably overcome. 262 using RepeatExplorer pipeline that utilizes NGS data to directly infer repeated elements 262 using RepeatExplorer pipeline that utilizes NGS data to directly infer repeated elements<br>263 that have been successfully utilized for developing highly sensitive diagnostic assays 263 that have been successfully utilized for developing highly sensitive diagnostic assays<br>264 [18-20], instead of assembled contigs of the genome, where highly repetitive sequenc 264 [18-20], instead of assembled contigs of the genome, where highly repetitive sequences<br>265 in genome assemblies are often omitted as orphan DNA during the assembly process. 265 in genome assemblies are often omitted as orphan DNA during the assembly process.<br>266 Diagnostic testing for onchocerciasis in regions co-endemic for *Loa* or 266 Diagnostic testing for onchocerciasis in regions co-endemic for *Loa* or 267 *Mansonella* spp can be challenging as mf of *M. streptocerca* typically migrate through 268 the skin [29], whereas mf from *M. perstans* and *L. loa* circulate in the vasculature [30]. 270 in nature especially in cases where the burden is high [1]. With the availability of better 271 repeat targets for detecting L. loa [15], M. perstans [21], the combination of Ov16R or 272 C150 New would be a great tool to not only help in more accurate diagnosis but to also 272 O150New would be a great tool to not only help in more accurate diagnosis but to also<br>273 advance the global efforts for mapping and elimination of neglected tropical diseases in 273 advance the global efforts for mapping and elimination of neglected tropical diseases in

274 areas co-endemic for filarial infections. Another bottleneck in the molecular<br>275 xenodiagnoses or xenomonitoring is the presence of other onchocerca species (O. 276 chengi, O. *quttarosa* etc) in the vectors. The use of OoR1 or OoR5 along with Ov16R 277 or O150New would help differentiate *O. ochengi* from *O. volvulus*). Alternatively, the use 278 of OvND5 (GenBank: AY462885.1 and FM206483.1) [31] that is slightly less sensitive 278 of OvND5 (GenBank: AY462885.1 and FM206483.1) [31] that is slightly less sensitive<br>279 but highly specific for *O. volvulus* or *O. ochengi* could be implemented as a second or 279 but highly specific for *O. volvulus* or *O. ochengi* could be implemented as a second or 280 confirmatory test to rule of *O. volvulus*.

282 peripheral circulation and have been used as good biomarkers in pregnancy, diabetes, 283 cancer and solid-organ transplantation (reviewed in [32-34]). Since the circulating cell-284 free DNA in the body fluids (plasma and/or urine) are short-lived and likely to be 285 excreted in urine, we evaluated the ability to detect Ov16R in plasma- and urine-derived 285 excreted in urine, we evaluated the ability to detect Ov16R in plasma- and urine-derived<br>286 ccfDNA of infected individuals to reflect the presence of active infection as the parasites 286 ccfDNA of infected individuals to reflect the presence of active infection as the parasites<br>287 release DNA (homeostatic and upon injury/death after treatment). However, we were 287 release DNA (homeostatic and upon injury/death after treatment). However, we were<br>288 runable to detect Ov16R reliably in ccfDNA derived from 250 ul of plasma. Increasing the 289 initial of plasma to 2 ml did not alter the outcome significantly, suggesting that the 289 initial of plasma to 2 ml did not alter the outcome significantly, suggesting that the<br>290 inability to detect Ov16R in plasma-derived ccfDNA may partly be due to the niche 290 inability to detect Ov16R in plasma-derived ccfDNA may partly be due to the niche of *O. volvulus* (skin-dwelling) in contrast to the blood vasculature dwelling filarial parasites<br>292 (W. bancrofti, B. malayi and L. loa). It is interesting that the novel repeat regions that 292 (*W. bancrofti*, *B. malayi* and *L. loa*). It is interesting that the novel repeat regions that 293 were identified earlier were also located in contigs that shared the O-150 repeat [16],<br>294 but were no better at detecting circulating parasite-derived DNA. 294 but were no better at detecting circulating parasite-derived DNA.<br>295

296 The kinetics of detecting Ov16R in urine after treatment with DEC and their<br>297 disappearance after 72 hours correlates well with the rapid death of the microfilaria 297 disappearance after 72 hours correlates well with the rapid death of the microfilariae<br>298 and subsequent clearance from circulation with the immunohistological and 298 and subsequent clearance from circulation with the immunohistological and<br>299 microscopical observations that the mf disappear within 3-days of microfilari 299 microscopical observations that the mf disappear within 3-days of microfilaricidal<br>300 treatment [35, 36]. 300 treatment [35, 36].<br>301

301 302 Nevertheless, in contrast to *L. loa* infections [15], urine proved to be a better<br>303 source for parasite-derived ccfDNA. While the lack of parasite derived ccfDNA in 304 plasma could be attributed to the niche of O. volvulus (in contrast to vascular dwelling 305 filaria such as W. bancrofti or L. loa), it is not clear as to why Ov16R was more readily 306 detectable in the limited number of more recent/fresh urine samples compared to 307 archived frozen urine samples. Previous studies demonstrated that the ccfDNA is 307 archived frozen urine samples. Previous studies demonstrated that the ccfDNA is<br>308 comprised of highly fragmented double stranded DNA around 150bp in length, tha 308 comprised of highly fragmented double stranded DNA around 150bp in length, that<br>309 relates to about 9,000-17,000 genome equivalents of human diploid genome in 1 m 309 relates to about 9,000-17,000 genome equivalents of human diploid genome in 1 ml of<br>310 blood [37, 38]. Though there is no established method of characterizing the nature of 311 parasite-derived ccfDNA in circulation, they are comparatively less abundant when 311 parasite-derived ccfDNA in circulation, they are comparatively less abundant when<br>312 compared to the host-derived ccfDNA. The rapid turnover and estimated renal 312 compared to the host-derived ccfDNA. The rapid turnover and estimated renal<br>313 clearance of ~30 minutes is an important feature of ccfDNA that can be exploit 313 clearance of ~30 minutes is an important feature of ccfDNA that can be exploited for<br>314 active cases of infection. The ccfDNA content is also known to vary as a function of 315 collection time, duration interval and storage conditions [39]. Prospectively, analyzing 316 larger volumes of urine samples using the chitosan filter-based method needs to be 316 larger volumes of urine samples using the chitosan filter-based method needs to be<br>317 evaluated for the efficiency of DNA capture. Moreover, once optimized, this would al 317 evaluated for the efficiency of DNA capture. Moreover, once optimized, this would also<br>318 facilitate easy storage of the filters compared to storing larger volumes in freezers. 318 facilitate easy storage of the filters compared to storing larger volumes in freezers.

319<br>320

- 320 **Acknowledgements**  321 This work was supported in part by the Division of Intramural Research (DIR) of the<br>322 National Institute of Allergy and Infectious Diseases, NIH.
- 
- 322 National Institute of Allergy and Infectious Diseases, NIH.<br>323 We thank Dr. Sara Lustigman from New York Blood Cente 323 We thank Dr. Sara Lustigman from New York Blood Center for fresh urine samples from<br>324 Cameroon.
- 324 Cameroon.<br>325
- 
- 325 All data produced in the present work are contained in the manuscript

327 REFERENCES<br>328 1. Nana-Djeunga HC, Fossuo-Thotchum F, Pion SD, Chesnais CB, Kubofcik J, Mackenzie CD,<br>329 et al. Loa loa Microfilariae in Skin Snips: Consequences for Onchocerciasis Monitoring and 329 1. In Nana-Djeunga He, Fossuo-Thomani, Pion Se, Phoenico-Thum F, Machenn, Machenzie CD,<br>329 1. et al. Loa loa Microfilariae in Skin Snips: Consequences for Onchocerciasis Monitoring and<br>330 1. Evaluation in L. loa-Ende 330 et aluation in L. loa-Endemic Areas. Clin Infect Dis. 2019;69(9):1628-30. doi: 10.1093/cid/ci<br>331 PubMed PMID: 30861060; PubMed Central PMCID: PMCPMC6792118. 330 Evaluation in L. loa-Endemic Areas. Clin Infect Dis. 2019;69(9):1628-30. doi: 10.1093/<br>331 PubMed PMID: 30861060; PubMed Central PMCID: PMCPMC6792118.<br>332 2. Taylor HR, Munoz B, Keyvan-Larijan

332 2. Taylor HR, Munoz B, Keyvan-Larijani E, Greene BM. Reliability of<br>333 microfilariae in skin snips in the diagnosis of onchocerciasis. Am J Trop I 333 and microfilariae in skin snips in the diagnosis of onchocerciasis. Am J Trop Med Hyg.<br>334 and 1989;41(4):467-71. doi: 10.4269/ajtmh.1989.41.467. PubMed PMID: 2802024.

333 microfilariae in skin snips in the diagnosis of onchocerciasis. Am J Trop Med Hyg.<br>334 1989;41(4):467-71. doi: 10.4269/ajtmh.1989.41.467. PubMed PMID: 2802024.<br>335 3. Guidelines for stopping mass drug administration an 336 onchocerciasis - Criteria and procedures, (1 January 2016, 2016).

337 4. Group NTDMCO. The World Health Organization 2030 goals for onchocerciasis: Insights<br>338 and perspectives from mathematical modelling: NTD Modelling Consortium Onchocerciasis 337 4. Group NTDMCO. The World Health Organization 2030 goa<br>338 and perspectives from mathematical modelling: NTD Modelling C 338 and perspectives from mathematical modelling: NTD Modelling Consortium Onchocerciasis<br>339 Group. Gates Open Res. 2019;3:1545. Epub 20190926. doi: 10.12688/gatesopenres.13067.1.

339 Group. Gates Open Res. 2019;3:1545. Epub 20190926. doi: 10.12688/gatesopenres.13067.1.<br>340 PubMed PMID: 31723729; PubMed Central PMCID: PMCPMC6820451.

341 5. Lobos E, Weiss N, Karam M, Taylor HR, Ottesen EA, Nutman TB. An immunogenic 341 **Burnham PubLe PubLe PubLe PubLe PubLe PubLe PubLe PubLe 2014**<br>341 5. Lobos E, Weiss N, Karam M, Taylor HR, Ottesen EA, Nutman TB.<br>342 Onchocerca volvulus antigen: a specific and early marker of infection. S 342 – Onchocerca volvulus antigen: a specific and early marker of infection. Science.<br>343 – 1991;251(5001):1603-5. doi: 10.1126/science.2011741. PubMed PMID: 2011741.

342 Onchocerca volvulus antigen: a specific and early marker of infection. Science.<br>343 1991;251(5001):1603-5. doi: 10.1126/science.2011741. PubMed PMID: 2011741.<br>344 6. Gbakima AA, Nutman TB, Bra

343 1991;251(5001):1603-5. doi: 10.1126/science.2011741. PubMed PMID: 2011741. 345 The manufacture Administration Constrainers (1989) (1999)<br>346 The Diagn Lab Immunol. 1996;3(1):98-104. doi: 10.1128/cdli.3.1.98-104.1996. PubMed 345 Immunoglobulin G subclass responses of children during infection with Onchocerca volvulus.<br>346 Clin Diagn Lab Immunol. 1996;3(1):98-104. doi: 10.1128/cdli.3.1.98-104.1996. PubMed PMID:<br>347 8770512; Pub

348 7. Weil GJ, Steel C, Liftis F, Li BW, Mearns G, Lobos E, et al. A rapid-format antibody card 347 8770512; PubMed Central PMCID: PMCPMC170255. 349 test for diagnosis of onchocerciasis. J<sup>'</sup>Infect Dis. 2000;182(6):1796-9. Epub 20001026. doi:<br>350 10.1086/317629. PubMed PMID: 11069258. 349 test for diagnosis of onchocerciasis. J Infect Dis. 2000;182(6):1796-9. Epub 20001026. doi:<br>350 10.1086/317629. PubMed PMID: 11069258.<br>351 8. Golden A, Steel C, Yokobe L, Jackson E, Barney R, Kubofcik J, et al. Extende

352 reading window in lateral flow tests detecting exposure to Onchocerca volvulus: a new<br>353 technology to improve epidemiological surveillance tools. PLoS One. 2013;8(7):e69231. 352 Freading window in lateral flow tests detecting exposure to Onchocerca volvulus: a new<br>353 Fechnology to improve epidemiological surveillance tools. PLoS One. 2013;8(7):e69231. Ep 353 technology to improve epidemiological surveillance tools. PLoS One. 2013;8(7):e69231.<br>354 20130723. doi: 10.1371/journal.pone.0069231. PubMed PMID: 23935960; PubMed Cer 354 20130723. doi: 10.1371/journal.pone.0069231. PubMed PMID: 23935960; PubMed Central<br>355 PMCID: PMCPMC3720650.

356 9. Katholi CR, Toe L, Merriweather A, Unnasch TR. Determining the prevalence of 2006 - PMCCOMMONIC COMPOSITION<br>356 - 9. Matholi CR, Toe L, M<br>357 - Onchocerca volvulus infecti 357 Discrete Catholical CR, Toe L, Merrime Catholic Catholic Catholic Creation Screen<br>358 pools of black flies. J Infect Dis. 1995;172(5):1414-7. doi: 10.1093/infdis/172.5.1414. Pi 357 Onchocerca volvulus infection in vector populations by polymerase chain reaction screening o<br>358 pools of black flies. J Infect Dis. 1995;172(5):1414-7. doi: 10.1093/infdis/172.5.1414. PubMed<br>359 PMID

360 10. Unnasch TR, Meredith SE. The use of degenerate primers in conjunction with strain and<br>361 species oligonucleotides to classify Onchocerca volvulus. Methods Mol Biol. 1996;50:293-303. 222<br>360 10. Unnasch<br>361 species oligonucl 361 Species oligonucleotides to classify Onchocerca volvulus. Methods Mol Biol. 1996;50:293-303.<br>362 doi: 10.1385/0-89603-323-6:293. PubMed PMID: 8751366.

362 doi: 10.1385/0-89603-323-6:293. PubMed PMID: 8751366.<br>363 11. Zimmerman PA, Guderian RH, Aruajo E, Elson L, Phadke P, Kubofcik J, et al. Polymerase 364 chain reaction-based diagnosis of Onchocerca volvulus infection: improved detection of<br>365 patients with onchocerciasis. J Infect Dis. 1994;169(3):686-9. doi: 10.1093/infdis/169.3.6 364 chain reaction-based diagnosis of Onchocerca volvulus infection: improved detection of<br>365 patients with onchocerciasis. J Infect Dis. 1994;169(3):686-9. doi: 10.1093/infdis/169.3.686. 365 patients with onchocerciasis. J Infect Dis. 1994;169(3):686-9. doi: 10.1093/infdis/169.3.6<br>366 PubMed PMID: 8158053. 366 PubMed PMID: 8158053.<br>367 12. Alhassan A, Makepeace BL, LaCourse EJ, Osei-Atweneboana MY, Carlow CK. A simple

367 12. Alhassan A, Maker<br>368 isothermal DNA amplifica<sup>.</sup> 368 isothermal DNA amplification method to screen black flies for Onchocerca volvulus infection. 368 isothermal DNA amplification method to screen black flies for Onchocerca volvulus infection.

369 PLoS One. 2014;9(10):e108927. Epub 20141009. doi: 10.1371/journal.pone.0108927. PubMed<br>370 PMID: 25299656; PubMed Central PMCID: PMCPMC4191976.<br>371 13. Wilson NO, Badara Ly A, Cama VA, Cantey P 371 13. Wilson NO, Badara Ly A, Cama VA, Cantey PT, Cohn D,<br>372 Lymphatic Filariasis and Onchocerciasis in Three Senegalese Di 372 Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerci<br>373 vith Ivermectin. PLoS Negl Trop Dis. 2016;10(12):e0005198. Epub 20161207. doi: 373 Lymphilvermectin. PLoS Negl Trop Dis. 2016;10(12):e0005198. Epub 20161207. doi:<br>374 L10.1371/journal.pntd.0005198. PubMed PMID: 27926918; PubMed Central PMCID: 374 10.1371/journal.phtd.0005198. PubMed PMID: 27926918; PubMed Central PMCII<br>375 PMCPMC5142766. 374 10.1371/journal.pntd.0005198. PubMed PMID: 27926918; PubMed Central PMCID:<br>375 PMCPMC5142766.<br>376 14. Khowawisetsut L, Sarasombath PT, Thammapalo S, Loymek S, Korbarsa T, Nochote H, et 376 14. Khowawise<mark>t</mark><br>377 al. Therapeutic trial 377 al. Therapeutic trial of doxycyclin plus ivermectin for the treatment of Brugia malayi naturally<br>378 infected cats. Vet Parasitol. 2017;245:42-7. Epub 20170818. doi: 10.1016/j.vetpar.2017.08.009. 377 al. Therapeutic trial of doxycyclin plus ivermectin for the treatment of Brugia malayi naturally<br>378 infected cats. Vet Parasitol. 2017;245:42-7. Epub 20170818. doi: 10.1016/j.vetpar.2017.08.009.<br>379 380 15. Bennuru S, Kodua F, Drame PM, Dahlstrom E, Nutman TB. A novel, bioinformatically  $381$  informed highly sensitive NAAT assay for the diagnosis of loiasis and its use for detection of 381 11. Bennamin S, Andrei, Schmitt, A., Schmitt, A., Schmitt, A., Schmitt, A., Schmitt, A., 2013<br>382 11. Bennaming cell free DNA. J Infect Dis. 2023. Epub 20230527. doi: 10.1093/infdis/jiad 186. 382 informed formed highly sensitive NAAT assets and the diagnost S82 informed to circulating cell free DNA. J<br>1983 PubMed PMID: 37243712. 382 circulating cell free DNA. J Infect Dis. 2023. Epub 20230527. doi: 10.1093/infdis/jiad1<br>383 PubMed PMID: 37243712.<br>384 16. Macfarlane CL, Quek S, Pionnier N, Turner JD, Wanji S, Wagstaff SC, et al. The 385 insufficiency of circulating miRNA and DNA as diagnostic tools or as biomarkers of treatment 385 insufficiency of circulating miRNA and DNA as diagnostic tools or as biomarkers of tre<br>386 efficacy for Onchocerca volvulus. Sci Rep. 2020;10(1):6672. Epub 20200421. doi: 386 efficacy for Onchocerca volvulus. Sci Rep. 2020;10(1):6672. Epub 20200421. doi:<br>387 10.1038/s41598-020-63249-4. PubMed PMID: 32317658; PubMed Central PMCID: 386 efficacy for Onchocerca volvulus. Sci Rep. 2020;10(1):6672. Epub 20200421. doi:<br>387 10.1038/s41598-020-63249-4. PubMed PMID: 32317658; PubMed Central PMCID:<br>388 PMCPMC7174290. 389 17. Tritten L, Burkman E, Moorhead A, Satti M, Geary J, Mackenzie C, et al. Detection of<br>390 circulating parasite-derived microRNAs in filarial infections. PLoS Negl Trop Dis. circulating parasite-derived microRNAs in filarial infections. PLoS Negl Trop Dis. 339 17. Tritten L, Burkman B, Moore Lives M, Satti M, Satti M, Satti M, Satti B, 2018.<br>390 10 17. Tritten L, Satti Machines, Satti M, Satti M, Satti M, Satti M, 2014;8(7):e2971. FubMed PMID: 391 circulating parasite-derived micropolitical micropolitics of the program.<br>392 circulating 25033073; PubMed Central PMCID: PMCPMC4102413. 391 2014;8(7):e2971. Epub 20140717. doi: 10.1371/journal.pntd.0002971. PubMed PMID:<br>392 25033073; PubMed Central PMCID: PMCPMC4102413.<br>393 18. O'Connell EM, Harrison S, Dahlstrom E, Nash T, Nutman T 2032 18. D'Connell EM, Harrison S, Dahlstrom E, Nash T, Nutman TB. A Novel, Highly Sensitive<br>394 Quantitative Polymerase Chain Reaction Assay for the Diagnosis of Subarachnoid and<br>395 Ventricular Neurocysticercosis and for 394 Quantitative Polymerase Chain Reaction Assay for the Diagnosis of Subarachnoid and<br>395 Ventricular Neurocysticercosis and for Assessing Responses to Treatment. Clin Infect Dis.<br>396 2020;70(9):1875-81. doi: 10.1093/cid/ 2020;70(9):1875-81. doi: 10.1093/cid/ciz541. PubMed PMID: 31232448; PubMed Central 398 19. Pilotte N, Maasch J, Easton AV, Dahlstrom E, Nutman TB, Williams SA. Targeting a highly 399 repeated germline DNA sequence for improved real-time PCR-based detection of Ascaris  $399$  repeated germline DNA sequence for improved real-time PCR-based detection of Ascaris<br>400 infection in human stool. PLoS Negl Trop Dis. 2019;13(7):e0007593. Epub 20190722. doi: 399 repeated germine During and sequence for improvements of interaction of the constant of the interaction in<br>401 10.1371/journal.pntd.0007593. PubMed PMID: 31329586; PubMed Central PMCID: infection in human stool. PLoS Negl Trop Dis. 2019;13(7):e0007593. Epub 20190722<br>10.1371/journal.pntd.0007593. PubMed PMID: 31329586; PubMed Central PMCID:<br>102 PMCPMC6675119.<br>103 20. Sears WJ, Qvarnstrom Y, Dahlstrom E, Sn 20. Sears WJ, Qvarnstrom Y, Dahlstrom E, Snook K, Kaluna L, Balaz V, et al. AcanR3990 111<br>403 20. Sears WJ, Q<br>404 qPCR: A Novel, High 404 apcR: A Novel, Highly Sensitive, Bioinformatically-Informed Assay to Detect Angiostrongyli<br>405 antonensis Infections. Clin Infect Dis. 2021;73(7):e1594-e600. doi: 10.1093/cid/ciaa1791. qPCR: A Novel, Highly Sensitive, Bioinformatically-Informed Assay to Detect Angiostrongylu<br>105 cantonensis Infections. Clin Infect Dis. 2021;73(7):e1594-e600. doi: 10.1093/cid/ciaa1791.<br>106 PubMed PMID: 33252651; PubMed Ce 21. Pilotte N, Thomas T, Zulch MF, Sirois AR, Minetti C, Reimer LJ, et al. Targeting a highly 408 repetitive genomic sequence for sensitive and specific molecular detection of the filarial<br>409 parasite Mansonella perstans from human blood and mosquitoes. PLoS Negl Trop Dis. 408 Prepetitive genomic sequence for sensitive and specific molecular detection of the filarial and thomas T, A<br>409 Parasite Mansonella perstans from human blood and mosquitoes. PLoS Negl Trop Dis. 409 repetitive generalises, and sensitive and specific molecular detection of the filarial<br>410 and 2022;16(12):e0010615. Epub 20221229. doi: 10.1371/journal.pntd.0010615. PubMed PN 409 parasite Mansonella perstans from human blood and mosquitoes. PLoS Negl Trop Dis. 36580452; PubMed Central PMCID: PMCPMC9833530. 411 36580452; PubMed Central PMCID: PMCPMC9833530.

412 22. Steel C, Lujan-Trangay A, Gonzalez-Peralta C, Zea-Flores G, Nutman TB. Immunologic<br>413 responses to repeated ivermectin treatment in patients with onchocerciasis. J Infect Dis.<br>414 1991;164(3):581-7. doi: 10.1093  $22.$ 415 23. Francis H, Awadzi K, Ottesen EA. The Mazzotti reaction following trea<br>416 – onchocerciasis with diethylcarbamazine: clinical severity as a function of infe 415 23. Francis H, Awadzi K, Ottesen EA. The Mazzotti reaction following treatment of<br>416 onchocerciasis with diethylcarbamazine: clinical severity as a function of infection inte 416 onchocerciasis with diethylcarbamazine: clinical severity as a function of infection inte<br>417 J Trop Med Hyg. 1985;34(3):529-36. doi: 10.4269/ajtmh.1985.34.529. PubMed PMID: 417 J Trop Med Hyg. 1985;34(3):529-36. doi: 10.4269/ajtmh.1985.34.529. PubMed PMID: 4003668.<br>418 24. Novak P, Neumann P, Pech J, Steinhaisl J, Macas J. RepeatExplorer: a Galaxy-based web 419 server for genome-wide characterization of eukaryotic repetitive elements from next-<br>420 generation sequence reads. Bioinformatics. 2013;29(6):792-3. Epub 20130201. doi: generation sequence reads. Bioinformatics. 2013;29(6):792-3. Epub 20130201. doi: 421 d0.1093/bioinformatics/btt054. PubMed PMID: 23376349.<br>422 35. Novak P, Neumann P, Macas J. Graph-based clusteri 25. Novak P, Neumann P, Macas J. Graph-based clustering and characterization of repetitive 423 Sequences in next-generation sequencing data. BMC Bioinformatics. 2010;11:378. Epub<br>424 20100715. doi: 10.1186/1471-2105-11-378. PubMed PMID: 20633259; PubMed Central PMCID: 423 sequences in next-generation sequencing data. BMC Bioinformatics. 2010;11:378. Epub 124 sequences in next-generation sequencing and the securencial serveration sequencies<br>424 september 20100715. doi: 10.1186/1471-2105-11-378. PubMed PMID: 20633259; PubMed Central<br>425 PMCPMC2912890. 424 20100715. doi: 10.1186/1471-2105-11-378. PubMed PMID: 20633259; PubMed Central PMC<br>425 PMCPMC2912890.<br>426 26. Gan W, Gu Y, Han J, Li CX, Sun J, Liu P. Chitosan-Modified Filter Paper for Nucleic Acid<br>427 Extraction and 426 26. Gan W, Gu <mark>\</mark><br>427 Extraction and "in S 427 Extraction and "in Situ PCR" on a Thermoplastic Microchip. Anal Chem. 2017;89(6):3568-75.<br>428 Epub 20170308. doi: 10.1021/acs.analchem.6b04882. PubMed PMID: 28230980. 428 Epub 20170308. doi: 10.1021/acs.analchem.6b04882. PubMed PMID: 28230980.<br>429 27. Rosenbohm JM, Robson JM, Singh R, Lee R, Zhang JY, Klapperich CM, et al. Rapid 430 electrostatic DNA enrichment for sensitive detection of Trichomonas vaginalis in clinical l<br>431 Samples. Anal Methods. 2020;12(8):1085-93. Epub 20200205. doi: 10.1039/c9ay02478f. 430 electrostatic DNA enrichment for sensitive detection of Trichomonas vaginalis in clinical urinary<br>431 samples. Anal Methods. 2020;12(8):1085-93. Epub 20200205. doi: 10.1039/c9ay02478f. 431 elemples. Anal Methods. 2020;12(8):1085-93. Epub 20200205. doi: 10.1039/c9ay02478f.<br>432 elebMed PMID: 35154421; PubMed Central PMCID: PMCPMC8837197. 432 PubMed PMID: 35154421; PubMed Central PMCID: PMCPMC8837197.<br>433 28. Deer DM, Lampel KA, Gonzalez-Escalona N. A versatile internal control for use as DNA in 434 The Pal-time PCR and as RNA in real-time reverse transcription PCR assays. Lett Appl Microbiol.<br>435 2010;50(4):366-72. Epub 20100122. doi: 10.1111/j.1472-765X.2010.02804.x. PubMed PMID: 434 real-time PCR and as RNA in real-time reverse transcription PCR assays. Lett Appl Microbiol.<br>435 2010:50(4):366-72. Epub 20100122. doi: 10.1111/j.1472-765X.2010.02804.x. PubMed PMID 435 2010;50(4):366-72. Epub 20100122. doi: 10.1111/j.1472-765X.2010.02804.x. PubMed PMID<br>436 20149084. 436 20149084.<br>437 29. Fischer P, Buttner DW, Bamuhiiga J, Williams SA. Detection of the filarial parasite 436 20149084. 438 Mansonella streptocerca in skin biopsies by a nested polymerase chain reaction-based as<br>439 Am J Trop Med Hyg. 1998;58(6):816-20. doi: 10.4269/ajtmh.1998.58.816. PubMed PMID 438 Mansonella streptocerca in skin biopsies by a nested polymerase chain reaction-based ass<br>439 Am J Trop Med Hyg. 1998;58(6):816-20. doi: 10.4269/ajtmh.1998.58.816. PubMed PMID:<br>440 9660471. 441 30. Zo<br>442 Distributic 441 30. Zoure HGM, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, et al. The Geographic 442 Distribution of Loa loa in Africa: Results of Large-Scale Implementation of the Rapid Assessmer<br>443 Procedure for Loiasis (RAPLOA). Plos Neglect Trop D. 2011;5(6). doi: ARTN e1210 442 Distribution of Loa loa in Africa: Results of Large-Scale Implementation of the Rap<br>443 Procedure for Loiasis (RAPLOA). Plos Neglect Trop D. 2011;5(6). doi: ARTN e1210<br>444 10.1371/journal.pntd.0001210. PubMed PMID: WOS 445 31. Hendy A, Kruger A, Pfarr K, De Witte J, Kibweja A, Mwingira U, et a<br>446 and transmission of Onchocerca volvulus in Mahenge, south eastern Tanz 445 31. Hendy A, Kruger A, Pfarr K, De Witte J, Kibweja A, Mwingira U, et al. The blackfly vectors 446 and transmission of Onchocerca volvulus in Mahenge, south eastern Tanzania. Acta Trop. 446 and transmission of Onchocerca volvulus in Mahenge, south eastern Tanzania. Acta Trop.<br>447 2018;181:50-9. Epub 20180202. doi: 10.1016/j.actatropica.2018.01.009. PubMed PMID: 447 and 2018;181:50-9. Epub 20180202. doi: 10.1016/j.actatropica.2018.01.009. PubMed PMID:<br>448 and 29410302. -----------<br>449 32. Arko<br>450 Circulating 449 32. Arko-Boham B, Aryee NA, Blay RM, Owusu EDA, Tagoe EA, Doris Shackie ES, et al. 450 Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and pr<br>451 Cancers. Cancer Genet. 2019;235-236:65-71. Epub 20190423. doi: 451 cancers. Cancer Genet. 2019;235-236:65-71. Epub 20190423. doi:<br>452 10.1016/j.cancergen.2019.04.062. PubMed PMID: 31105051. 11 cancers. Cancer Cancer Cancer Cancer Cancer Cancer Cancer Cancer<br>453 d. 23. Edwards RL, Menteer J, Lestz RM, Baxter-Lowe LA. Cell-free 452 10.1016/j.cancergen.2019.04.062. PubMed PMID: 31105051. 454 11 Edwards R. Menteer J, Lestz RM, Lands R. Menteer Province Processing Carry 1946<br>454 120220223. doi: 10.2217/bmm-2021-0968. PubMed PMID: 35195028. 454 transplant biomarker: technologies and approaches. Biomark Med. 20<br>455 20220223. doi: 10.2217/bmm-2021-0968. PubMed PMID: 35195028.

455 20220223. doi: 10.2217/bmm-2021-0968. PubMed PMID: 35195028.

456 456 34. Padilla-Martinez F, Wojciechowska G, Szczerbinski L, Kretowski A. Circulating Nucleic<br>457 Acid-Based Biomarkers of Type 2 Diabetes. Int J Mol Sci. 2021;23(1). Epub 20211228. doi:<br>458 10.3390/ijms23010295. P 34. 458 10.3390/ijms23010295. PubMed PMID: 35008723; PubMed Central PMCID: PMCPMC8745431.<br>459 35. Buttner G, Zea-Flores G, Poltera AA, Buttner DW. Fine structure of microfilariae in the<br>460 skin of onchocerciasis patients afte Buttner G, Zea-Flores G, Poltera AA, Buttner DW. Fine structure of microfilariae in the 460 skin of onchocerciasis patients after exposure to amocarzine. Trop Med Parasitol.<br>1991;42(3):314-8. PubMed PMID: 1801159.<br>162 36. Darge K. Lucius R. Monson MH. Behrendsen J. Buttner DW. Immunohistolc 36. Darge K, Lucius R, Monson MH, Behrendsen J, Buttner DW. Immunohistological and 463 electron microscopic studies of microfilariae in skin and lymph nodes from onchocerciasis<br>464 patients after ivermectin treatment. Trop Med Parasitol. 1991;42(4):361-7. PubMed PMID: 463 electron microscopic studies of microfilariae in skin and lymph nodes from onchocerciasis 111 electron microscopic studies of microfilariae in successive, proportion on the section of patients after ivermectin treatment. Trop Med Parasitol. 1991;42(4):361-7. PubMed PMID<br>465 1796234. 464 patients after ivermectin treatment. Trop Med Parasitol. 1991;42(4):361-7. PubMed PMID:<br>465 1796234.<br>466 37. Volik S, Alcaide M, Morin RD, Collins C. Cell-free DNA (cfDNA): Clinical Significance and 465 1796234. 111 1111 11111, Alcaide M, Morther, Collins Collins Collins, Chemin, Collins Communist International<br>468 20160715. doi: 10.1158/1541-7786.MCR-16-0044. PubMed PMID: 27422709. 467 Utility in Cancer Shaped By Emerging Technologies. Mol Cancer Res. 2016;14(10):898-908. Epu<br>468 20160715. doi: 10.1158/1541-7786.MCR-16-0044. PubMed PMID: 27422709.<br>469 38. Azad AA, Volik SV, Wya 470 Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in<br>471 Gastration-Resistant Prostate Cancer. Clin Cancer Res. 2015;21(10):2315-24. Epub 20150223. 470 Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in<br>471 Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015:21(10):2315-24. Epub 2015( 471 Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015;21(10):2315-24. Epub 2015<br>472 doi: 10.1158/1078-0432.CCR-14-2666. PubMed PMID: 25712683. 472 doi: 10.1158/1078-0432.CCR-14-2666. PubMed PMID: 25712683.<br>473 39. Augustus E, Van Casteren K, Sorber L, van Dam P, Roeyen G, Peeters M, et al. The art of 474 bbtaining a high yield of cell-free DNA from urine. PLoS One. 2020;15(4):e0231058. Epub<br>475 20200406. doi: 10.1371/journal.pone.0231058. PubMed PMID: 32251424; PubMed Central 474 obtaining a high yield of cell-free DNA from urine. PLoS One. 2020;15(4):e0231058. Epub<br>475 20200406. doi: 10.1371/journal.pone.0231058. PubMed PMID: 32251424; PubMed Cent 475 20200406. doi: 10.1371/journal.pone.0231058. PubMed PMID: 32251424; PubMed Centr<br>476 PMCID: PMCPMC7135229. 476 PMCID: PMCPMC7135229. PubMed PMID: 2324. PubMed Central.political.political.political.political.political.<br>477 477<br>477

- 477<br>478
- 

478

480



## 481<br>482

482 **Figure 1**<br>483 Identification of *Onchocerca volvulus* and *Onchocerca ochengi* repeat elements. (A) 483 Identification of *Onchocerca volvulus* and *Onchocerca ochengi* repeat elements. (A) 484 The graph depicts the screening of the identified repeat elements for limits of detection<br>485 (plotted as Ct-values on the y-axis) by qPCR using dilutions of *O. volvulus* gDNA. (B) 485 (plotted as Ct-values on the y-axis) by qPCR using dilutions of *O. volvulus* gDNA. (B) 486 The graph represents the efficiency of the top five assays targeting repeated elements<br>487 in comparison with O-150. (C) The graph depicts the specificity of Ov16R and Ov15R 487 in comparison with O-150. (C) The graph depicts the specificity of Ov16R and Ov15R<br>488 with serial dilutions of gDNA across major filarial parasites of humans. (D) The bar 488 with serial dilutions of gDNA across major filarial parasites of humans. (D) The bar<br>489 araph depicts the screening of the identified repeat elements for limits of detection 490 (plotted as Ct-values on the y-axis) by qPCR using O. ochengi (blue) and O. volvulus 490 (plotted as Ct-values on the y-axis) by qPCR using *O. ochengi* (blue) and *O. volvulus* 491 (red) gDNA. (E) The bar graph shows the limits of detection (plotted as Ct-values on the<br>492 y-axis) of *O. ochengi* repeat assays (OoR1 and OoR5) by qPCR using dilutions of *O.* 492 y-axis) of *O. ochengi* repeat assays (OoR1 and OoR5) by qPCR using dilutions of *O.*  493 *ochengi* (red and blue) and *O. volvulus* (green and black) gDNA. No amplifications were 494 set to 40 cycles.<br>495



## 497<br>498

Figure 2<br>499 Development of new assays for O. volvulus. (A) The graph represents the efficiency of

500 the Ov16R (red) and Ov15R (blue) in comparison with O-150 (green) across different

501 concentrations of O. volvulus gDNA. (B) Screening of re-designed O-150 new assays

501 concentrations of *O. volvulus* gDNA. (B) Screening of re-designed O-150 new assays 502 (O-150 N1-N5) for limits of detection (plotted as Ct-values on the y-axis) in comparison<br>503 with Ov15R and current O-150 qPCR assay

503 with Ov15R and current O-150 qPCR assay<br>504

505



## 506<br>507

507 **Figure 3**<br>508 Efficiency of Ov16R and O-150New *(A)* The VENN diagram denotes the O-150 qPCR 509 status of skin snips (top panel), with Ov16R detecting 17 additional samples missed by 510 O-150. (B/C) The graph represents the paired Ct values obtained by Ov16R and O150, 510 O-150. (B/C) The graph represents the paired Ct values obtained by Ov16R and O150,<br>511 and the 17 additional samples being detected by Ov16R that were O-150 negative. (D) 511 and the 17 additional samples being detected by Ov16R that were O-150 negative. (D)<br>512 Ov16R sensitivity is improved (Ct values) compared to O-150 but does not detect any 512 Ov16R sensitivity is improved (Ct values) compared to O-150 but does not detect any<br>513 new additional samples from *Loa loa* co-infected area. (E) Graph depicts the correlation 513 new additional samples from *Loa loa* co-infected area. (E) Graph depicts the correlation<br>514 of the O150 assay with that of O-150New and Ov16R. (F&G) The graph shows the 514 of the O150 assay with that of O-150New and Ov16R. (F&G) The graph shows the<br>515 paired comparison of O150New with O-150 (O-150\_OLD) or Ov16R. 515 paired comparison of O150New with O-150 (O-150\_OLD) or Ov16R.<br>516





## 517<br>518

518 **Figure 4**<br>519 Efficacy of ccfDNA from plasma and urine. (A) the graph represents the Ov16R qPCR 520 status (Ct values) of ccfDNA extracted from 1000 ul, 500 ul, 250 ul and 100 ul of pooled 521 sera (n=10) from Ov-infected individuals from Guatemala (G86), Ecuador (EC92) or 522 pooled plasma of healthy blood bank volunteers  $(n=10)$  with or without Ov-gDNA 523 spiked. (B) the graph represents the Ov16R gPCR status (Ct value) with ccfDNA 524 extracted from 1 ml of urine from Ov-infected individuals before treatment (C&D) the 525 time course results of Ov16R qPCR with ccfDNA extracted from post-treatment samples 525 time course results of Ov16R qPCR with ccfDNA extracted from post-treatment samples<br>526 (E) the graph represents the Ov16R status of 5 fresh urine samples from Cameroon. 526 (E) the graph represents the Ov16R status of 5 fresh urine samples from Cameroon.<br>527<br>.





528<br>529

529 **Figure 5**<br>530 Efficacy of ccfDNA from chitosan-modified filter membrane. The graph shows the

531 Ov16R qPCR (Ct values) of DNA extracted from 1 ml or 15 ml of normal urine spiked 531 Ov16R qPCR (Ct values) of DNA extracted from 1 ml or 15 ml of normal urine spiked<br>532 with varying concentrations of gDNA. The dotted lines denote the Ct values of

- 532 with varying concentrations of gDNA. The dotted lines denote the Ct values of<br>533 respective concentrations of gDNA.
- 533 respective concentrations of gDNA.<br>534
-